A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy
Status:
Completed
Trial end date:
2018-01-08
Target enrollment:
Participant gender:
Summary
The investigators study will recruit IgA nephropathy patients with proteinuria range from
0.75 to 3.5g/d even after three-month treatment by sufficient ACEi/ARB. The patients were
treated with Hydroxychloroquine 200-400mg/d according to eGFR. The proteinuria will recorded
every two months and total four months. Then, the drug will be stopped for two months for
observation of change of proteinuria.